glp-1 elisa kit Human GLP-1 ELISA Kit (BMS2194)

We can anticipate the development of novel formulations, combination therapies, and orally available options that could further improve convenience and accessibility

[DOI] [PubMed] [Google Scholar] Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W, Jang HJ, Mattson MP, Drucker DJ, Egan JM, et al

But those studies used oral supplements at specific doses, not transdermal patches

Nausea, vomiting, and diarrhea were typically the most common gastrointestinal adverse events, occurring in up to 48.4%, 23.2%, and 23.1% of participants, respectively, with events occurring predominantly during dose escalation and decreasing over time [10, 37, 43, 4547]

With these results, Lilly now has the full data package needed for global regulatory submissions

So why do people not persist with it